MYCOPHENOLATE MOFETIL

PRODUCT IDENTIFICATION
CAS NO. 128794-94-5

MYCOPHENOLATE MOFETIL

EINECS NO.  
FORMULA C23H31NO7
MOL WT. 433.49

H.S. CODE

 2934.99.0100

TOXICITY

  
SYNONYMS Myfenax;

Mycophenolate mofetil; Mycophenolic acid 2-morpholinoethyl ester;

4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5- isobenzofuranyl)-4- methyl-, 2-(4-morpholinyl)ethyl ester; 2-Morpholinoethyl (E)-6-(l,3-dihydro-4-hydroxy-6- methoxy-7- methyl-3- oxo-5-isobenzofuranyl)-4- methyl-4-hexenoate; (4E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl- 3-oxo-5-isobenzofuranyl) -4-methyl-4-hexenoic acid 2- (4-morpholinyl)ethyl esterOther RN: 115007-34-6, 140401-05-4
SMILES

C1OCCN(C1)CCOC(CCC(\C)=C/Cc1c(c(c2c(c1O)C(OC2)=O)C)OC)=O

CLASSIFICATION

Immunomodulator

EXTRA NOTES

Mycophenolic acid that is chemically altered by the addition of morpholinoethylester; selective and reversible inhibitor of inosine monophosphate dehydrogenase.

PHYSICAL AND CHEMICAL PROPERTIES
PHYSICAL STATE White to off-white crystalline powder
MELTING POINT  
BOILING POINT  
SPECIFIC GRAVITY  
SOLUBILITY IN WATER  
pH  
VAPOR DENSITY

 

AUTOIGNITION

 

NFPA RATINGS

Health hazard: 2, Flammability: 0, Physical hazards: 0

REFRACTIVE INDEX

  
FLASH POINT

 

STABILITY Stable under ordinary conditions.

EXTERNAL LINKS & GENERAL DESCRIPTION

Wikipedia Linking

Google Scholar Search

Drug Information Portal (U.S. National Library of Medicine) - Mycophenolate mofetil

PubChem Compound Summary - Mycophenolate mofetil

Drug Bank -  Mycophenolic acid

KEGG (Kyoto Encyclopedia of Genes and Genomes) -  Mycophenolate mofetil

http://www.ebi.ac.uk/ -  Mycophenolate mofetil

http://www.ncbi.nlm.nih.gov/ -  Mycophenolate mofetil

http://www.sigmaaldrich.com/
Mycophenolate mofetil is a prodrug of mycophenolic acid that is cleaved by nonspecific esterases in vivo to produce the parent compound. Mycophenolic acid blocks inosine monophosphate dehydrogenase and is a potent immunosuppresive agent.

http://www.gene.com/
Mycophenolate mofetil has been demonstrated in experimental animal models to prolong the survival of allogeneic transplants (kidney, heart, liver, intestine, limb, small bowel, pancreatic islets, and bone marrow). Mycophenolate mofetil has also been shown to reverse ongoing acute rejection in the canine renal and rat cardiac  allograft models. Mycophenolate mofetil also inhibited proliferative arteriopathy in experimental models of aortic and cardiac allografts in rats, as well as in primate cardiac xenografts. Mycophenolate mofetil was used alone or in combination with other immunosuppressive agents in these studies. Mycophenolate mofetil has been demonstrated to inhibit immunologically mediated inflammatory responses in animal models and to inhibit tumor development and prolong survival in murine tumor transplant models.

Local:
Mycophenolate, 2-morpholinoethyl ester of mycophenolic acid, is a guanine monophosphate synthesis inhibitor by interfering with the synthesis of  inosine mononophosphate dehydrogenase (IMPDH), resulting in inhibiting the proliferation of cells, especially leukocytes and lymphocytes. It is more lymphocyte-specific than azathioprine. Mycophenolate is an immunosuppressive agent used in conjunction with cyclosporine and corticosteroids to prevent rejection of allogeneic renal transplants. Mycophenolate mofetil is a white to off-white crystalline powder; soluble in acetone and methanol, and sparingly soluble in water and ethanol; administered orally. The chemical designation is 2-morpholinoethyl (E)-6-(l,3-dihydro-4-hydroxy-6-methoxy-7- methyl-3-oxo-5-isobenzofuranyl)-4- methyl-4-hexenoate.
SALES SPECIFICATION

APPEARANCE

 White to off-white crystalline powder

IDENTIFICATION

Complies

ASSAY (HPLC)

 97.5 - 100.5%

LOSS ON DRYING

2.0% max
HEAVY METALS

20ppm max
RELATED SUBSTANCES 1.0% max (FREE ACID: 0.5 max)
TRANSPORTATION
PACKING

 

HAZARD CLASS  
UN NO.  
GENERAL DESCRIPTION OF IMMUNOSUPPRESSIVE DRUGS
Immunosuppressants are drugs to prevent transplant rejection after organ transplantation by inhibiting the reaction of the immune system and suppression of body's ability to recognize and destroy foreign substances. But they also reduce the ability of the immune system to fight infections, resulting in vulnerable body to opportunistic infections and risk of developing certain cancers. Most of immunosuppressants suppress the whole immune system. Globulin types used in combination with other immunosuppressants and monoclonal antibodies suppress specific parts of the immune system. Immunosuppressions are also used to counteract autoimmune diseases characterized by an overactive immune response, whereby the body own immune defense mechanisms are inappropriately directed against the normal tissue that lines the joints and connective tissue in many other parts of the body, such as the blood vessels and lungs, resulting in organ damage or activation of a systemic immune response. Immunosuppressive drugs can be classified into groups as follows:
  • Corticosteroids
    • Dexamethasone
    • Prednisolone
    • Prednisone
  • Polyclonal antibodies
    • Antilymphocyte globulin
    • Antithymocyte globulin
  • Macrolides
    • Sirolimus
    • Tacrolimus
  • Antimetabolites
    • Azathioprine
    • Cyclophosphamide
    • Methotrexate
  • Monoclonal antibodies
    • Basiliximab
    • Daclizumab
    • Infliximab
    • Muromonab
  • Fungal metabolite
    • Cyclosporine
  • Others
    • Glatiramer acetate
    • Mycophenolate mofetil
    • Interferons
    • Opioids
    • Tumor necrosis factor (TNF) inhibitors
SAFETY INFORMATION

HAZARD OVERVIEW

Toxic by ingestion

GHS

 
SIGNAL WORD Warning

PICTOGRAMS

HAZARD STATEMENTS

H302-H400

P STATEMENTS

P273

PRICE INFORMATION